Previous 10 | Next 10 |
home / stock / lly / lly articles
Monday, Biohaven’s (NYSE:BHVN) CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company...
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer. &quo...
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...
In a significant development, Medicare may extend coverage for Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (sem...
Eli Lilly and Co. (NYSE:LLY) enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound — the latter already recording stellar sal...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. "We ...
Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash p...
Eli Lilly And Co’s (NYSE:LLY) much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return o...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...